Medipharm Labs Corp Stock Performance
| MEDIF Stock | USD 0.05 0 2.22% |
The company secures a Beta (Market Risk) of -0.0596, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Medipharm Labs are expected to decrease at a much lower rate. During the bear market, Medipharm Labs is likely to outperform the market. At this point, Medipharm Labs Corp has a negative expected return of -0.1%. Please make sure to verify Medipharm Labs' coefficient of variation, maximum drawdown, skewness, as well as the relationship between the total risk alpha and downside variance , to decide if Medipharm Labs Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Medipharm Labs Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Stock's forward indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
| Begin Period Cash Flow | 19.9 M | |
| Total Cashflows From Investing Activities | 35 K | |
| Free Cash Flow | -14 M |
Medipharm |
Medipharm Labs Relative Risk vs. Return Landscape
If you would invest 5.10 in Medipharm Labs Corp on September 19, 2024 and sell it today you would lose (0.50) from holding Medipharm Labs Corp or give up 9.8% of portfolio value over 90 days. Medipharm Labs Corp is currently producing negative expected returns and takes up 3.5705% volatility of returns over 90 trading days. Put another way, 31% of traded otc stocks are less volatile than Medipharm, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Medipharm Labs Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medipharm Labs' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Medipharm Labs Corp, and traders can use it to determine the average amount a Medipharm Labs' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0284
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MEDIF |
Estimated Market Risk
| 3.57 actual daily | 31 69% of assets are more volatile |
Expected Return
| -0.1 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Medipharm Labs is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medipharm Labs by adding Medipharm Labs to a well-diversified portfolio.
Medipharm Labs Fundamentals Growth
Medipharm OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Medipharm Labs, and Medipharm Labs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medipharm OTC Stock performance.
| Return On Equity | -0.57 | |||
| Return On Asset | -0.24 | |||
| Profit Margin | (2.07) % | |||
| Operating Margin | (1.61) % | |||
| Current Valuation | 3.05 M | |||
| Shares Outstanding | 280.51 M | |||
| Price To Book | 0.36 X | |||
| Price To Sales | 0.69 X | |||
| Revenue | 21.71 M | |||
| EBITDA | (38.55 M) | |||
| Cash And Equivalents | 21.99 M | |||
| Cash Per Share | 0.08 X | |||
| Total Debt | 1.44 M | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 0.22 X | |||
| Cash Flow From Operations | (13.21 M) | |||
| Earnings Per Share | (0.14) X | |||
| Total Asset | 92.36 M | |||
About Medipharm Labs Performance
By analyzing Medipharm Labs' fundamental ratios, stakeholders can gain valuable insights into Medipharm Labs' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Medipharm Labs has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Medipharm Labs has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada, Australia, Germany, and internationally. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada. MEDIPHARM LABS is traded on OTC Exchange in the United States.Things to note about Medipharm Labs Corp performance evaluation
Checking the ongoing alerts about Medipharm Labs for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Medipharm Labs Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medipharm Labs Corp generated a negative expected return over the last 90 days | |
| Medipharm Labs Corp has some characteristics of a very speculative penny stock | |
| Medipharm Labs Corp has high historical volatility and very poor performance | |
| The company reported the revenue of 21.71 M. Net Loss for the year was (54.8 M) with loss before overhead, payroll, taxes, and interest of (13.42 M). | |
| Medipharm Labs Corp has accumulated about 21.99 M in cash with (13.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Medipharm Labs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medipharm Labs' stock is overvalued or undervalued compared to its peers.
- Examining Medipharm Labs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medipharm Labs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medipharm Labs' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Medipharm Labs' otc stock. These opinions can provide insight into Medipharm Labs' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Medipharm OTC Stock analysis
When running Medipharm Labs' price analysis, check to measure Medipharm Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medipharm Labs is operating at the current time. Most of Medipharm Labs' value examination focuses on studying past and present price action to predict the probability of Medipharm Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medipharm Labs' price. Additionally, you may evaluate how the addition of Medipharm Labs to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Stocks Directory Find actively traded stocks across global markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |